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Rats, sheep and guinea pigs treated with swajnson~e excre$e ‘high close’ o~gosa~h~id~ in urine. The 
major rat and guinea pig oligosaccharide is (Man$GlcNAc, whereas heep excrete a mixture of 
oligosaccharides of composition (Man)~_sGlcNAc~ and (Man)~_~GlcNAc. The presence of these 
oligosaccharides suggests that Golgi zu-ISmannosidase II as well as lysosomal -R-mannosidase i  inhibited 
by awalnsonine r sulting in storage of abnormally processed asparagine-linked glycans from glycoproteins. 
Altered giycoprotein processing appears to have Iittle effect on the health of the intoxicated animal, but 
the a~rn~~~~~ lysosomal storage produces a disease state. 
1, I~TRGDUCTIU~ 2. EATERIES AND ~THUDS 
The plant alkaloid, swainsonine (indolizidine- 
1,2,8-trial), is a potent and specific inhibitor of 
m-D-mannosidase [I 1. Prolonged ingestion of 
swainsonine by animals causes alysosomal storage 
ph~~orneno~ with cytoplasmic Y~~u~iatio~ f 
most tissue cells, neurology degeneration a d a 
clinical neurologic deficit typical of genetic man- 
nosidosis 121. This disease process can be related 
salely to the i~~bi~on of lysosomal cu-D-manno- 
sidase 131.. 
All chemicals used were of analytical grade ob- 
tained fram BDH or Sigma of Poole (Dar@. 
Sw~nso~~e also inhibits the ~y~protei~ pro- 
cessing a-D-mannasidase II in vitro f4] and in 
cultured cells, resulting in the synthesis of 
glycoproteins containing ‘high maninnose’ and 
hybrid asparagine-linked glycans [5,6]. We have 
shown that purified swainsonine causes torage of 
ab~o~~ly processed man~ose-Rich oligosac- 
charides in cells in culture ~~~p~~~~~~}” 
Here, we show that swainsanine affects 
gly~apratein processing in viva and we discuss the 
role of altered processing in sw~nsa~ne toxicosis. 
Weanling merino lambs, guinea pigs and 
Sprague-Dawley strain rats were fed ad fibitum 
cammereial f~dstuffs ~ont~~~ 33% by wt, mill- 
ed, air-dried ~~~~o~~ canescens. The rations 
contained -8 mg sw~nsonin~kg~ The animals 
were fed for 6 weeks and then returned to their 
normal commercial diet. During the feeding period 
18 h urine samples were collected by the use of 
m~abol~m cages designed to separate urine from 
faeces. Urine was stored at -20°C for later use. 
Urinary oligosaccharides were analysed by thin- 
layer chromatography (TLC), gel filtration, gas- 
liquid chromatography (GLC) and GLC-mass 
spectrametry as in [8,9]. Fast-atom-bamb~dme~t 
(PAI%) mass-sp~tromet~ was performed as in 
flOl. 
Authentic samples of oligu~~~h~ides isolated 
from the urine of human ma~osidosis patients 
were kindly provided by Drs 3.-C, ~ich~ski and 
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G, Strecker (La~oratoire de Chimie Biologique, 
Lille). 
3. RESULTS AND DISCUSSION 
3.1. ~wai~onine-induced xcretion of neutral 
Guinea pigs, rats and sheep fed a diet containing 
Swainsona for 6 weeks excreted large amounts of 
neutral oligosaccharides in their urine (fig. 1). 
These oligosaccharides were absent or present in 
much lower concentrations in the urine of control 
animals. It was concluded that ingestion of swain- 
sonine resulted in inhibition of lysosomal cu-D- 
mannosidase and the accumulation i  the tissues 
and excretion in urine of mannose-rich oligosac- 
charides, as in genetic mannosidosis. The pattern 
of excreted oligosac~h~ides was very similar in the 
guinea pig and rat. The predominant oligosac- 
charide (I) had the same mobility as an authentic 
sample of a human urinary oligosaccharide of
composition (Man)SGlcNAc (MsG). The pattern of 
excreted oligosaccharides was more complicated 
for the sheep. In particular, one of the major 
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Fig-l. TLC of neutral ol~gosacch~ides in urine of 
swainsonine-fed guinea pigs, rats and sheep. TLC was 
carried out on silica gel with n-propanol : Hz0 (7 : 3, v/v) 
as the solvent. Carbohydrate was detected with orcinol 
[0.2% (w/v) in H2SO4 (970, v/v, in methanol)]: (1) 
authentic oligosaccharides, MzG, MsG and isomeric 
mixture of MsG; (2,3) control and swa~so~ne-treated 
rat urine; (4,s) control and sw~nsonine-tr~ted guinea 
pig urine; (6,7) control and swainsonine-treated sheep 
urine; (8) MsG. 
oligosacch~ides (I) appeared to be larger, but 
oligosaccharides corresponding to those in the rat 
and guinea pig were also detected (II, III, IV). 
Little material corresponding to Man(rul-3)Man- 
(cul-4)GlcNAc (MzG), the predominant urinary 
oligosaccharide in human genetic mannosidosis, 
was detected in any of the urines of sw~nso~ne- 
treated animals. Thus the pattern of excreted oli- 
gosaccharides is different in swainsonine-induced 
and genetic mannosidosis. 
The level of neutral oligosaccharides in sheep 
urine was monitored by TLC before and during in- 
gestion of ~wain~ona and after its removal from 
the diet. The main oligosaccharides, I and II, ap- 
peared in the urine within 1 week of the introduc- 
tion of Swainsona into the diet and reached acon- 
stant level within 2 weeks. This level did not 
change appreciably over a period of 2-6 weeks on 
the diet. After withdrawal of ~wainsona from the 
diet, the levels of the oligosaccharides began to 
decrease within 2 days and the pattern returned 
progressively to normal over a period of 3 weeks. 
The larger oligosaccharides disappeared most 
rapidly. These observations confirmed that swain- 
sonine induced the excretion of neutral oligosac- 
charides and showed that the phenomenon was 
reversible. 
3.2. Nature of the swainsonine-induced oiigo- 
The main oligosaccharides (I) in the urine of 
swainsonine-treated rats and guinea pigs were 
purified by a combination of ion-exchange, gel- 
filtration and preparative TLC 191. Carbohydrate 
analyses were determined by GLC and GLC-mass 
sp~romet~ (table 1). Only mannose and N- 
acetylglucosamine w re present in detectable quan- 
tities. The composition of rat and guinea pig I was 
consistent with it being MansGlcNAc. The masses 
of the rat and guinea pig I were determined by 
FAB mass-spectroscopy of mixtures of oligosac- 
char-ides I-III (fig. l), obtained by gel filtration on 
Bio-gel P4. FAB mass-spectrometry confirmed 
that the main rat and guinea pig oligosaccharide 
had the composition (ManhGlcNAc and showed 
that rat and guinea pig components II and III had 
masses consistent with compositions of 
(Man~GlcNAc and (M~~3GlcNAc, respectively. 
The main sheep urinary oligosaccharides were 
also purified and analysed by GLC and shown to 
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Table I 
Analysis of swai~son~e-i~du~ urinary oligosaecharide 
ManlGIcNAc Moiecular ions Composition 
from GLC obtained by 
FAB mass 
spectrometry 
m&M + H*) 
Authentic dligosaccharides 
Man2GlcNAc 2.15 (3) 
Man>GkNAc 3.0 (3) 
MansGlcNAc 5.05 (22 
546 
708 
1032 
Guinea pi8 I 4.95 (2) 1032 Man~GicNAc 
II - 870 MamGlcNAc 
III - 708 MansGlcNAc 
Rat 1 
TI 
IIf 
Sheep I
II 
III 
IV 
5.25 
- 
- 
2.45 (1) 
2.60 (3) 
1.30 (I) 
1.05 (1) 
1032 MansGlcNAc 
870 Man.+GlcNAc 
708 ManjGlcNAc 
1235 MansGIcNAcz 
1073 MamGlcNAcz 
911 MansGlcNAcz 
749 Man2GlcNAcz 
contain only mannose and N-acetylglucosamine. 
However, the Man/GlcNAc ratios suggested a 
higher GlcNAc content and that the separated 
oiigos~~~h~ides were heterogeneous. This was 
confirmed by FAB mass-spectrometry which 
showed that components I-IV corresponded to 
MansGlcNAcz, Man+GIcNAcz, Man3fGlcNAcz 
and ManzGlcNAc~, respectively but that smaller 
amounts of Mans_,GlcNAc were also present. 
Complex glycans are normally twice as abun- 
dant as high mannose glycans in mammalian 
gly~o~roteins f 111. However, the expected storage 
product from the catabolism of complex glycans in 
the presence of a swainsonine-induced eficiency 
of Iysosomal cu-D-mannosidase, MsG 
~~{~1-3}~Man(~l-~]Man~l-4)GlcNA~) is 
not as abundant as the oligosaccharide, 
Mau~GlcNAc. The excretion of o~~osacch~des 
containing 5 mannose residues uggests that swain- 
sonine has blocked the conversion of high man- 
nose asparagine-linked glycans to the complex type 
by inhibiting Golgi cu-D-mannosidase II. Thus 
swainsonine-induced m~osidosis results in the 
accumulation and excretion of oligosaccharides 
derived from abnormally processed glycoproteins. 
The excretion by sheep of oligosaccharides con- 
taining two GlcNAc units could be due to the 
absence or overloading of the catabolic endohex- 
osaminidase that catalyses the hydrolysis of the 
core chitobiosidi~ linkage. A similar deficiency of 
this enzymic activity has been observed in other 
ruminants in caprine ,&mannosidosis [12] and 
bovine ~-m~~nosidosis [9]. 
The implications of high maunose oligo- 
saccharide storage in vivo are far reaching. The 
marked similarities between the morphologic and 
clinical expression of swainsonine intoxication and 
genetic mannosidosis have been noted for many 
years [133. It is possible to make a direct com- 
parison between the two forms of mannoside 
storage only in cattle, since in this species both 
forms have been reported [14,15]. ~though 
glycoprotein processing is affected in Sovainsona 
poisoning all the significant characteristics of 
~~~~~0~~ poisoning are also present in genetic 
lysosomal a-D-mannosidase deficiency. Even 
animals treated with purified swainsonine for 
periods of up to 120 days, apart from having a 
retarded growth rate and extensive tissue vacuola- 
tion, show clinical or patholo~c~ changes only in 
the central nervous system [la]. This suggests that 
the abnormal processing of glycoproteins in the 
presence of swainsonine has little effect on the 
health of the animals and that Swa~~o~~ toxicosis 
is essentially a storage disease. This conclusion is 
inconsistent with the assertion in [17] that 
‘the pathological effects of swainsonine are not 
solely att~butable to its being an inhibitor of 
lysosomal ru-D-maunosidase and are probably a 
consequence of abnormal processing of 
glycoproteins’. 
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